XML 227 R43.htm IDEA: XBRL DOCUMENT
v3.25.1

Corporate and Group Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Corporate and Group Information [Abstract] |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies | As of the date of this report, the Company had direct and indirect interests in its subsidiaries, all of which are private limited liability companies, the particulars of which are set out below:
|  |  |  |  |  |  |  | Percentage |  |
|  |  |  |  |  |  |  | of equity |  |
|  |  |  | Date and place of |  | Issued ordinary |  | attributable to |  |
|  |  |  | incorporation / registration |  | share/ |  | the Company |  |
Name |  | Notes |  | and place of operations |  | registered capital |  | Direct |  | Indirect |  | Principal activities
Alpine Bioscience Ltd. (“Alpine BVI”) |  |  |  | British Virgin Islands 8 January 2018 |  | One share of par value $1 |  | 100 | % | — |  | Investment holding
Adlai Nortye USA Inc (“Adlai US”) |  |  |  | The United States 30 January 2018 |  | 10,000 shares of par value $0.0001 each |  | — |  | 100 | % | Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”) |  |  |  | Switzerland 21 June 2022 |  | 100 shares of par value CHF1’000 each |  | — |  | 100 | % | Investment holding
Adlai Nortye PTE.LTD (“Adlai SGP”) |  |  |  | Singapore 22 April 2022 |  | Two shares of par value $1 |  | — |  | 100 | % | Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”) |  |  |  | Hong Kong 24 April 2018 |  | HKD 0.001 |  | — |  | 100 | % | Investment holding
Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”) |  |  |  | the People’s Republic of China (“PRC”)/Mainland China 14 September 2004 |  | RMB 200,000 |  | — |  | 100 | % | Product research and development, technology transfer and consulting services business
Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”) |  |  |  | the People’s Republic of China (“PRC”)/Mainland China 22 December 2021 |  | RMB 10,000 |  | — |  | 100 | % | Product research and development, technology transfer and consulting services business
| * | The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.

X
- References No definition available. + Details
Name: | ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of interests in subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 2 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_2_b_i&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration